Seborrheic Dermatitis on the FacePilot RCTNCT07433907
Efficacy of an Antioxidant Moisturizing Serum for Mild to Moderate Seborrheic Dermatitis
A study testing Antioxidant moisturizing serum in people with Seborrheic Dermatitis on the Face, run by Institute of Dermatology, Thailand at 1 site in Thailand.
Trial summary
This is a 4-week comparison study between the intervention and control sides of the face. Purposive sampling to recruit 13 patients with seborrheic dermatitis will be conducted in this study. The study will start after researcher has been granted the Ethic Committee Approval. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Seborrheic Dermatitis on the Face
- What is being tested?
- Antioxidant moisturizing serum
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 13 participants
- Where
- 1 siteThailand
- Study dates
- 6 Mar 2026to 7 Jul 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age: ≥ 18 years old
- Gender: Male and Female
- Patient who never uses or has stopped using topical corticosteroids/calcineurin inhibitor or other topical treatments exerting anti-inflammatory action (on the face) more than 2 weeks before entering this clinical trials.
- Patient who does not use cosmetic containing any oxidants or others that exert anti-oxidant effect(s). If there is any, one must refrain from using them more than 2 weeks before entering this clinical trials.
Who cannot join
- Patients with known cases of underlying HIV/AIDS, neurological condition e.g., Parkinson's disease.
- Patient associated with any autoimmune diseases and other skin diseases
- Patient takes any forms of oral immunotherapy more than 2 months up to the first day of clinical trials.
- Patients continuously use of topical corticosteroids or other anti-inflammatory medicines on regular basis up to the first day of clinical trial.
- Patient who refuses to stop using cosmetic(s) containing anti-oxidants or those exert anti-oxidant effect(s).
- Patient who is allergic to the test product or one of its ingredients.
- Pregnancy or nursing woman
Trial locations and contacts
1 site in 1 country.
About this study
Official title: A Prospective, Randomized, Split-Face Pilot Study Comparing the Efficacy of the Institute of Dermatology's Antioxidant Moisturizing Serum in Mild to Moderate Seborrheic Dermatitis
This is a 4-week comparison study between the intervention and control sides of the face. Purposive sampling to recruit 13 patients with seborrheic dermatitis will be conducted in this study. The study will start after researcher has been granted the Ethic Committee Approval. The process of subject recruitment and clinical data collection will take place at the Outpatient Department (OPD) while photograph taking and skin measurement will take place at Laser Center and Bioengineering Department, respectively. All bioengineering instruments will be operated under the climate controlled environment; i.e, at temperature 20+/-2 degree Celsius and 50+/-2 % of relative humidity. A subject must get acclimatized to the ambient atmosphere for at least 30 minutes. The clinical data, skin barrier function, the quality of life, subject's satisfaction scale will be collected at the first day (D0, as baseline) and 4th week after finishing the test product (Wk4).
- Conditions
- Seborrheic Dermatitis on the Face
- Being tested
- Antioxidant moisturizing serum
- Keywords
- seborrheic dermatitis, SEDASI score, antioxidant, skin hydration, split-face randomized controlled trial, Transepidermal water loss
- Medical subject headings
- Dermatitis, Seborrheic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Antioxidant moisturizing serumOther
Antioxidant Moisturizing Serum
| Study group | Role | What they receive |
|---|---|---|
| Intervention group | Experimental | Not described Receives: Other: Antioxidant moisturizing serum |
What is being measured
The primary outcome is the main question the study is designed to answer.
SEDASI score
To compare clinical improvement as assessed by SEDASI score, between the intervention and control sides of the face in subjects with mild to moderate seborrheic dermatitis after 4 weeks of application of Institute of Dermatology's antioxidant moisturizing serum. This study uses split-face design. Due to the split-face study design and use of the SEDASI score, the same scoring scales were applied for extension (area, 0-6), presentation pattern (0-3), erythema (0-3), and scaling (0-3). The nasal area was excluded because split application to the nose is impractical. The original severity classification was therefore divided by two to obtain a hemiface-specific severity classification. Note: As the nasal area represents approximately 1% of the facial surface and the study compares the two sides of the face, this modification does not affect the primary study objective. The total score may range from 0 (no Seborrheic Dermatitis) to 30 (Seborrheic Dermatitis of the worst possible degree).
Measured: 1 year
Secondary outcomes (1)
Skin Barrier function
To evaluate skin barrier function, as measured by transepidermal water loss (TEWL) and skin hydration, and surface lipid after 4 weeks of using IOD's antioxidant moisturizing serum.
To evaluate facial skin appearance-including glossiness, desquamation, roughness, smoothness, wrinkles, elasticity, and redness-after 4 weeks of using IOD's antioxidant moisturizing serum.
Measured: 4 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Feb 2026
- Study start6 Mar 2026
- Primary completion7 Jul 2026
- Study completion7 Jul 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (43)Papers the sponsor has linked to this study.
- Other trials for Seborrheic Dermatitis on the FaceStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 13 participants (actual)
Sponsor and investigators
- Lead sponsor
- Institute of Dermatology, Thailand
- Sponsor type
- Other government
- Responsible party
- Sponsor
- Investigators
- Veng Ang Lok, Medical Doctor, Principal investigator, Rangsit University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07433907
- Sponsor's protocol ID
- 026/2568
- Acronym
- Pilot RCT
- Status last verified
- Jul 2026
- First submitted
- 19 Feb 2026
- Last updated
- 28 Jul 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: We are not allowed to share IPD without participants' permission in advance.
Publications
Yan H, Zhang S, Sun W, Li J, Xu J, Bi Y, Wu X, Song B. A bibliometric and visual analysis of the research status and hotspots of seborrheic dermatitis based on web of science. Skin Res Technol. 2024 Sep;30(9):e70048. doi: 10.1111/srt.70048.
PubMed 39252564Woolhiser E, Keime N, Patel A, Weber I, Adelman M, Dellavalle RP. Nutrition, Obesity, and Seborrheic Dermatitis: Systematic Review. JMIR Dermatol. 2024 Aug 5;7:e50143. doi: 10.2196/50143.
PubMed 39102684Wikramanayake TC, Borda LJ, Miteva M, Paus R. Seborrheic dermatitis-Looking beyond Malassezia. Exp Dermatol. 2019 Sep;28(9):991-1001. doi: 10.1111/exd.14006. Epub 2019 Aug 19.
PubMed 31310695Trusler AR, Clark AK, Sivamani RK, Shi VY. The Endocannabinoid System and Its Role in Eczematous Dermatoses. Dermatitis. 2017 Jan/Feb;28(1):22-32. doi: 10.1097/DER.0000000000000257.
PubMed 28098721Tosti A, Schwartz JR. Role of scalp health in achieving optimal hair growth and retention. Int J Cosmet Sci. 2021 Nov;43 Suppl 1:S1-S8. doi: 10.1111/ics.12708.
PubMed 33932025Szepietowski JC, Reich A, Wesolowska-Szepietowska E, Baran E; National Quality of Life in Dermatology Group. Quality of life in patients suffering from seborrheic dermatitis: influence of age, gender and education level. Mycoses. 2009 Jul;52(4):357-63. doi: 10.1111/j.1439-0507.2008.01624.x. Epub 2008 Sep 12.
PubMed 18793259Schwartz JR, Messenger AG, Tosti A, Todd G, Hordinsky M, Hay RJ, Wang X, Zachariae C, Kerr KM, Henry JP, Rust RC, Robinson MK. A comprehensive pathophysiology of dandruff and seborrheic dermatitis - towards a more precise definition of scalp health. Acta Derm Venereol. 2013 Mar 27;93(2):131-7. doi: 10.2340/00015555-1382.
PubMed 22875203Sanders MGH, Pardo LM, Ginger RS, Kiefte-de Jong JC, Nijsten T. Association between Diet and Seborrheic Dermatitis: A Cross-Sectional Study. J Invest Dermatol. 2019 Jan;139(1):108-114. doi: 10.1016/j.jid.2018.07.027. Epub 2018 Aug 18.
PubMed 30130619Rusic D, Ivic M, Slugan A, Leskur D, Modun D, Durdov T, Vukovic D, Bukic J, Bozic J, Seselja Perisin A. Pilot Study on the Effects of a Cosmetic Serum Containing Niacinamide, Postbiotics and Peptides on Facial Skin in Healthy Participants: A Randomized Controlled Trial. Life (Basel). 2024 Dec 18;14(12):1677. doi: 10.3390/life14121677.
PubMed 39768384Rousel J, Nadaban A, Saghari M, Pagan L, Zhuparris A, Theelen B, Gambrah T, van der Wall HEC, Vreeken RJ, Feiss GL, Niemeyer-van der Kolk T, Burggraaf J, van Doorn MBA, Bouwstra JA, Rissmann R. Lesional skin of seborrheic dermatitis patients is characterized by skin barrier dysfunction and correlating alterations in the stratum corneum ceramide composition. Exp Dermatol. 2024 Jan;33(1):e14952. doi: 10.1111/exd.14952. Epub 2023 Nov 16.
PubMed 37974545Ezerskaia A, Ras A, Bloemen P, Pereira SF, Urbach HP, Varghese B. High sensitivity optical measurement of skin gloss. Biomed Opt Express. 2017 Aug 7;8(9):3981-3992. doi: 10.1364/BOE.8.003981. eCollection 2017 Sep 1.
PubMed 29026683Ormel J, Jeronimus BF, Kotov R, Riese H, Bos EH, Hankin B, Rosmalen JGM, Oldehinkel AJ. Neuroticism and common mental disorders: meaning and utility of a complex relationship. Clin Psychol Rev. 2013 Jul;33(5):686-697. doi: 10.1016/j.cpr.2013.04.003. Epub 2013 Apr 29.
PubMed 23702592Campione E, Mazzilli S, Lanna C, Cosio T, Palumbo V, Cesaroni G, Lozzi F, Diluvio L, Bianchi L. The Effectiveness of a New Topical Formulation Containing GSH-C4 and Hyaluronic Acid in Seborrheic Dermatitis: Preliminary Results of an Exploratory Pilot Study. Clin Cosmet Investig Dermatol. 2019 Dec 16;12:881-885. doi: 10.2147/CCID.S231313. eCollection 2019.
PubMed 31920359Pizzino G, Irrera N, Cucinotta M, Pallio G, Mannino F, Arcoraci V, Squadrito F, Altavilla D, Bitto A. Oxidative Stress: Harms and Benefits for Human Health. Oxid Med Cell Longev. 2017;2017:8416763. doi: 10.1155/2017/8416763. Epub 2017 Jul 27.
PubMed 28819546Pigatto PD, Diani M. Beneficial Effects of Antioxidant Furfuryl Palmitate in Non-pharmacologic Treatments (Prescription Emollient Devices, PEDs) for Atopic Dermatitis and Related Skin Disorders. Dermatol Ther (Heidelb). 2018 Sep;8(3):339-347. doi: 10.1007/s13555-018-0239-0. Epub 2018 May 22.
PubMed 29790104
Study at a glance
From the registry record, last updated by the sponsor on 28 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Prospective, Randomized, Split-Face Pilot Study Comparing the Efficacy of the Institute of Dermatology's Antioxidant Moisturizing Serum in Mild to Moderate Seborrheic Dermatitis
- ClinicalTrials.gov ID
- NCT07433907
- Acronym / sponsor ID
- Pilot RCT / 026/2568
- Conditions
- Seborrheic Dermatitis on the Face
- Keywords
- seborrheic dermatitis, SEDASI score, antioxidant, skin hydration, split-face randomized controlled trial, Transepidermal water loss
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 13 participants (actual)
- Lead sponsor
- Institute of Dermatology, ThailandOther government
- Study start
- 6 Mar 2026 (actual)
- Primary completion
- 7 Jul 2026 (actual)
- Study completion
- 7 Jul 2026 (actual)
- First posted
- 25 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a 4-week comparison study between the intervention and control sides of the face. Purposive sampling to recruit 13 patients with seborrheic dermatitis will be conducted in this study. The study will start after researcher has been granted the Ethic Committee Approval. The process of subject recruitment and clinical data collection will take place at the Outpatient Department (OPD) while photograph taking and skin measurement will take place at Laser Center and Bioengineering Department, respectively. All bioengineering instruments will be operated under the climate controlled environment; i.e, at temperature 20+/-2 degree Celsius and 50+/-2 % of relative humidity. A subject must get acclimatized to the ambient atmosphere for at least 30 minutes. The clinical data, skin barrier function, the quality of life, subject's satisfaction scale will be collected at the first day (D0, as baseline) and 4th week after finishing the test product (Wk4).
Study design
- Primary purpose
- Health services research
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Intervention group | Experimental | Other: Antioxidant moisturizing serum |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Age: ≥ 18 years old
- Gender: Male and Female
- Patient who never uses or has stopped using topical corticosteroids/calcineurin inhibitor or other topical treatments exerting anti-inflammatory action (on the face) more than 2 weeks before entering this clinical trials.
- Patient who does not use cosmetic containing any oxidants or others that exert anti-oxidant effect(s). If there is any, one must refrain from using them more than 2 weeks before entering this clinical trials.
Key exclusion criteria (7 listed)
- Patients with known cases of underlying HIV/AIDS, neurological condition e.g., Parkinson's disease.
- Patient associated with any autoimmune diseases and other skin diseases
- Patient takes any forms of oral immunotherapy more than 2 months up to the first day of clinical trials.
- Patients continuously use of topical corticosteroids or other anti-inflammatory medicines on regular basis up to the first day of clinical trial.
- Patient who refuses to stop using cosmetic(s) containing anti-oxidants or those exert anti-oxidant effect(s).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Antioxidant moisturizing serumAntioxidant Moisturizing Serum | Other | Intervention group |
Primary outcome
SEDASI score
Time frame: 1 year
To compare clinical improvement as assessed by SEDASI score, between the intervention and control sides of the face in subjects with mild to moderate seborrheic dermatitis after 4 weeks of application of Institute of Dermatology's antioxidant moisturizing serum. This study uses split-face design. Due to the split-face study design and use of the SEDASI score, the same scoring scales were applied for extension (area, 0-6), presentation pattern (0-3), erythema (0-3), and scaling (0-3). The nasal area was excluded because split application to the nose is impractical. The original severity classification was therefore divided by two to obtain a hemiface-specific severity classification. Note: As the nasal area represents approximately 1% of the facial surface and the study compares the two sides of the face, this modification does not affect the primary study objective. The total score may range from 0 (no Seborrheic Dermatitis) to 30 (Seborrheic Dermatitis of the worst possible degree).
1 secondary outcome
Skin Barrier function
Time frame: 4 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Jul 2026.
- Background: PubMed 39252564Yan H, Zhang S, Sun W, Li J, Xu J, Bi Y, Wu X, Song B. A bibliometric and visual analysis of the research status and hotspots of seborrheic dermatitis based on web of science. Skin Res Technol. 2024 Sep;30(9):e70048. doi: 10.1111/srt.70048.
- Background: PubMed 39102684Woolhiser E, Keime N, Patel A, Weber I, Adelman M, Dellavalle RP. Nutrition, Obesity, and Seborrheic Dermatitis: Systematic Review. JMIR Dermatol. 2024 Aug 5;7:e50143. doi: 10.2196/50143.
- Background: PubMed 31310695Wikramanayake TC, Borda LJ, Miteva M, Paus R. Seborrheic dermatitis-Looking beyond Malassezia. Exp Dermatol. 2019 Sep;28(9):991-1001. doi: 10.1111/exd.14006. Epub 2019 Aug 19.
- Background: PubMed 28098721Trusler AR, Clark AK, Sivamani RK, Shi VY. The Endocannabinoid System and Its Role in Eczematous Dermatoses. Dermatitis. 2017 Jan/Feb;28(1):22-32. doi: 10.1097/DER.0000000000000257.
- Background: PubMed 33932025Tosti A, Schwartz JR. Role of scalp health in achieving optimal hair growth and retention. Int J Cosmet Sci. 2021 Nov;43 Suppl 1:S1-S8. doi: 10.1111/ics.12708.
- Background: PubMed 18793259Szepietowski JC, Reich A, Wesolowska-Szepietowska E, Baran E; National Quality of Life in Dermatology Group. Quality of life in patients suffering from seborrheic dermatitis: influence of age, gender and education level. Mycoses. 2009 Jul;52(4):357-63. doi: 10.1111/j.1439-0507.2008.01624.x. Epub 2008 Sep 12.
- Background: PubMed 22875203Schwartz JR, Messenger AG, Tosti A, Todd G, Hordinsky M, Hay RJ, Wang X, Zachariae C, Kerr KM, Henry JP, Rust RC, Robinson MK. A comprehensive pathophysiology of dandruff and seborrheic dermatitis - towards a more precise definition of scalp health. Acta Derm Venereol. 2013 Mar 27;93(2):131-7. doi: 10.2340/00015555-1382.
- Background: PubMed 30130619Sanders MGH, Pardo LM, Ginger RS, Kiefte-de Jong JC, Nijsten T. Association between Diet and Seborrheic Dermatitis: A Cross-Sectional Study. J Invest Dermatol. 2019 Jan;139(1):108-114. doi: 10.1016/j.jid.2018.07.027. Epub 2018 Aug 18.
- Background: PubMed 39768384Rusic D, Ivic M, Slugan A, Leskur D, Modun D, Durdov T, Vukovic D, Bukic J, Bozic J, Seselja Perisin A. Pilot Study on the Effects of a Cosmetic Serum Containing Niacinamide, Postbiotics and Peptides on Facial Skin in Healthy Participants: A Randomized Controlled Trial. Life (Basel). 2024 Dec 18;14(12):1677. doi: 10.3390/life14121677.
- Background: PubMed 37974545Rousel J, Nadaban A, Saghari M, Pagan L, Zhuparris A, Theelen B, Gambrah T, van der Wall HEC, Vreeken RJ, Feiss GL, Niemeyer-van der Kolk T, Burggraaf J, van Doorn MBA, Bouwstra JA, Rissmann R. Lesional skin of seborrheic dermatitis patients is characterized by skin barrier dysfunction and correlating alterations in the stratum corneum ceramide composition. Exp Dermatol. 2024 Jan;33(1):e14952. doi: 10.1111/exd.14952. Epub 2023 Nov 16.
- Background: PubMed 29026683Ezerskaia A, Ras A, Bloemen P, Pereira SF, Urbach HP, Varghese B. High sensitivity optical measurement of skin gloss. Biomed Opt Express. 2017 Aug 7;8(9):3981-3992. doi: 10.1364/BOE.8.003981. eCollection 2017 Sep 1.
- Background: PubMed 23702592Ormel J, Jeronimus BF, Kotov R, Riese H, Bos EH, Hankin B, Rosmalen JGM, Oldehinkel AJ. Neuroticism and common mental disorders: meaning and utility of a complex relationship. Clin Psychol Rev. 2013 Jul;33(5):686-697. doi: 10.1016/j.cpr.2013.04.003. Epub 2013 Apr 29.
- Individual participant dataSharing planned: No. We are not allowed to share IPD without participants' permission in advance.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Veng Ang Lok, Medical Doctor principal investigator
Rangsit University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Antioxidant moisturizing serum in people with Seborrheic Dermatitis on the Face, run by Institute of Dermatology, Thailand at 1 site in Thailand.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 28 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Thailand. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
SEDASI score (time frame: 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07433907, which also lists 43 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Jul 2026.